23,106 Shares in Johnson & Johnson $JNJ Purchased by Elite Wealth Management Inc.

Key Points

• Elite Wealth Management bought 23,106 Johnson & Johnson shares in the third quarter, worth about $6.12 million and representing 1.2% of its portfolio.
• J&J reported quarterly EPS of $2.59, beating estimates of $2.53, while revenue rose 5.9% year over year to $25.40 billion. The company set 2026 EPS guidance of $11.05–$11.15.
• Analysts have a consensus Moderate Buy rating and an average price target of $275.92. J&J also declared a quarterly dividend of $1.34 per share, equivalent to a 1.9% annualized yield.

Elite Wealth Management Inc. acquired a new stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 23,106 shares of the company's stock, valued at approximately $6,117,000. Johnson & Johnson makes up 1.2% of Elite Wealth Management Inc.'s investment portfolio, making the stock its 25th largest position.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Wellington Management Group LLP increased its stake in shares of Johnson & Johnson by 12.5% in the 2nd quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company's stock valued at $5,736,851,000 after purchasing an additional 2,513,321 shares during the last quarter. Deutsche Bank AG lifted its position in shares of Johnson & Johnson by 8.5% during the 2nd quarter. Deutsche Bank AG now owns 15,661,323 shares of the company's stock worth $3,977,506,000 after buying an additional 1,225,676 shares during the last quarter. Amundi lifted its position in shares of Johnson & Johnson by 17.5% during the 1st quarter. Amundi now owns 13,406,820 shares of the company's stock worth $3,277,163,000 after buying an additional 2,001,139 shares during the last quarter. Janus Henderson Group PLC boosted its stake in Johnson & Johnson by 1.9% in the first quarter. Janus Henderson Group PLC now owns 7,872,478 shares of the company's stock valued at $1,924,323,000 after buying an additional 148,497 shares in the last quarter. Finally, Jupiter Topco LLC acquired a new stake in Johnson & Johnson in the second quarter valued at about $1,967,399,000. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the company. TD Cowen reiterated a "buy" rating on shares of Johnson & Johnson in a research report on Tuesday, October 20th. Leerink Partners dropped their target price on shares of Johnson & Johnson from $276.00 to $272.00 and set an "outperform" rating for the company in a report on Wednesday, October 14th. UBS Group set a $270.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 14th. Weiss Ratings lowered shares of Johnson & Johnson from a "buy (b+)" rating to a "buy (b-)" rating in a report on Friday, October 23rd. Finally, Royal Bank Of Canada lowered their price objective on shares of Johnson & Johnson from $290.00 to $280.00 and set an "outperform" rating for the company in a research report on Wednesday, October 14th. One investment analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $275.92.

Johnson & Johnson Price Performance

Shares of JNJ opened at $276.14 on Monday. The company has a debt-to-equity ratio of 0.44, a current ratio of 1.02 and a quick ratio of 0.74. Johnson & Johnson has a 1 year low of $185.12 and a 1 year high of $282.02. The business has a 50-day moving average of $265.91 and a 200-day moving average of $248.30. The company has a market capitalization of $664.76 billion, a price-to-earnings ratio of 41.84, a price-to-earnings-growth ratio of 2.73 and a beta of 0.22.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, beating analysts' consensus estimates of $2.53 by $0.06. The company had revenue of $25.40 billion for the quarter, compared to analyst estimates of $25.38 billion. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The company's quarterly revenue was up 5.9% on a year-over-year basis. During the same period in the prior year, the firm posted $2.80 EPS. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. As a group, equities research analysts anticipate that Johnson & Johnson will post 11.12 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Shareholders of record on Tuesday, November 24th will be paid a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a yield of 1.9%. Johnson & Johnson's payout ratio is 81.21%.

Insiders Place Their Bets

In related news, EVP Jennifer Taubert sold 15,000 shares of the business's stock in a transaction on Monday, August 17th. The shares were sold at an average price of $263.36, for a total transaction of $3,950,400.00. Following the transaction, the executive vice president owned 194,451 shares in the company, valued at $51,210,615.36. The trade was a 7.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Timothy Schmid sold 33,597 shares of the stock in a transaction dated Wednesday, September 2nd. The stock was sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the transaction, the executive vice president directly owned 25,447 shares in the company, valued at $6,991,308.78. This trade represents a 56.90% decrease in their position. The SEC filing for this sale provides additional information. 0.16% of the stock is owned by insiders.

Johnson & Johnson News Summary

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: The FDA granted accelerated approval to RYBREVANT FASPRO as a single-agent treatment for certain adults with recurrent or metastatic head and neck cancer after prior platinum chemotherapy and immunotherapy. J&J says the treatment is the first new option in this setting in a decade; trial data showed a 42% response rate. The approval extends the drug’s use beyond lung cancer and could broaden its commercial opportunity, though the indication is limited and accelerated approval may require confirmatory evidence. FDA approval announcement
• Positive Sentiment: J&J’s Innovative Medicine division grew third-quarter sales 7.7% to $16.76 billion, with established blockbusters and new launches more than offsetting generic competition. Continued growth despite patent-related headwinds supports the business outlook. Innovative Medicine sales report
• Neutral Sentiment: J&J was included in an article highlighting companies with a history of dividend increases and strong balance sheets. This reinforces its income-investor appeal, but the article does not identify a new company-specific dividend announcement. Dividend raisers article
• Negative Sentiment: Pomerantz LLP announced it is investigating potential claims on behalf of J&J investors. The notice does not provide details of the claims, but the investigation could add legal and reputational uncertainty. Investor investigation announcement

About Johnson & Johnson

Johnson & Johnson is a global healthcare company that develops and sells prescription medicines and medical technologies. Its business is organized around two segments: Innovative Medicine and MedTech.

Innovative Medicine develops treatments in areas including oncology, immunology, neuroscience, cardiovascular and metabolic disease, and pulmonary hypertension. MedTech provides products and technologies for fields such as surgery, orthopedics, and vision care.

Founded in 1886, Johnson & Johnson serves patients and healthcare professionals in markets around the world.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.